Director's Buying Activity at Outlook Therapeutics Highlights Ongoing Development Efforts
A director at Outlook Therapeutics, Inc. recently purchased a notable quantity of the company's common stock. This transaction occurs amidst significant corporate developments, including an FDA victory concerning its product LYTENAVA and a recent downgrade from BTIG. The purchases, coupled with clinical progress, offer insight into internal confide…